a year ago
JNJ
AnalystsAsad HaiderAsad Haider's Stock Forecasts
AnalystsAsad Haider
Sectors:
Industries:
Analyst Ranking
Top 38%
#2003 out of 5298 analysts
Average Return
+19.57%
Win Rate
71%5 out of 7
Risk vs Reward
Poor
Good
Asad Haider's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Johnson & JohnsonJNJ | +59.83% | $150.97 | $241.30 | 2025-04-08 - 2026-04-08 | Strong Buy |
Royalty Pharma PLCRPRX | +53.66% | $35.28 | $54.21 | 2025-09-29 - 2026-06-16 | Strong Buy |
Eli Lilly & CoLLY | +28.21% | $726.24 | $931.09 | 2025-04-07 - 2026-04-07 | Strong Buy |
Johnson & JohnsonJNJ | +23.08% | $191.08 | $235.18 | 2025-10-08 - 2026-06-16 | Strong Buy |
Johnson & JohnsonJNJ | +13.96% | $206.37 | $235.18 | 2025-12-18 - 2026-06-16 | Strong Buy |
Asad Haider Analyst Color
Get additional color on Asad Haider's coverage of popular stocks
a year ago
LLY
a year ago
PFE
Asad Haider's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biontech SeBNTX | 2 | Strong Buy | $142.00 | +58.66% | Upgrades | 5 months ago |
Johnson & JohnsonJNJ | 3 | Strong Buy | $240.00 | +2.05% | Maintains | 6 months ago |
Newamsterdam Pharma Co NvNAMS | 2 | Hold | $37.00 | +22.56% | Maintains | 7 months ago |
Bristol Myers Squibb CoBMY | 2 | Hold | $57.00 | +1.93% | Maintains | 7 months ago |
Innoviva IncINVA | 1 | Strong Sell | $17.00 | -24.81% | Initiates Coverage On | 9 months ago |
Royalty Pharma PLCRPRX | 1 | Strong Buy | $42.00 | -22.52% | Initiates Coverage On | 9 months ago |
Vaxcyte IncPCVX | 1 | Hold | $38.00 | -22.94% | Initiates Coverage On | 9 months ago |
Eli Lilly & CoLLY | 1 | Strong Buy | $888.00 | N/A | Upgrades | a year ago |
Abbvie IncABBV | 1 | Hold | $194.00 | N/A | Assumes | a year ago |
Pfizer IncPFE | 1 | Hold | $25.00 | N/A | Downgrades | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.